| Community-Acquired PneumoniaThe Harrison's Practice Preview allows you to view 5 FREE complete topics or conduct a search that delivers abstracts for more than 450 medical topics.
For full access, please subscribe today!
 |
Prognosis
- Outpatients
- Young, otherwise healthy adults
- Those treated as outpatients usually feel well enough to return to work in 4 or 5 days; almost all recover in 2 weeks.
- Those with relatively severe symptoms may require longer to recover.
- ~24% of those treated as outpatients experience a progression of symptoms and require hospital admission.
- Inpatients
- Patients generally stabilize within 37 days.
- The in-hospital mortality rate from pneumonia is ~8%.
- The most common immediate causes of death are respiratory failure, heart disease, and sepsis.
- ~50% of deaths are related to pneumonia and ~50% to comorbid illnesses.
- Pneumonia-related deaths are much more likely to occur during the first week of hospitalization.
- Increasing age and evidence of aspiration independently predict both pneumonia-related and comorbidity-related mortality.
- Factors independently associated with pneumonia-unrelated mortality include:
- Dementia
- Immunosuppression
- Active cancer
- Systolic hypotension
- Male gender
- Multilobar pulmonary infiltrates
- Mortality associated with PORT score (see Treatment Approach)
- Class I: 00.5%
- Class II: 0.40.9%
- Class III: 01.25%
- Class IV: 9.012.5%
- Class V: 27.1%
- Mortality is related to the specific etiology.
- Rates are highest (>50%) for P. aeruginosa, followed by Klebsiella spp., E. coli, S. aureus, and Acinetobacter spp. (all 3035%).
- Pneumococcal capsular serotype 3 is associated with a much higher mortality rate than serotype 1, as are group A streptococcal M serotypes 1 and 3 (compared with other serotypes).
- Early, appropriate antibiotic therapy is associated with decreased mortality rates.
The Harrison's Practice Preview allows you to view 5 FREE complete topics or conduct a search that delivers abstracts for more than 450 medical topics.
For full access, please subscribe today!
 |
| |